Adaptable Leukemia Cells Resisting CAR T-cell Attack via B-cell Activation.
Ziran ZhaoJan Joseph MelenhorstPublished in: Cancer immunology research (2022)
Chimeric antigen receptor (CAR) T-cell therapy has achieved remarkable milestones in the treatment of B-cell malignancies. However, cancer cells frequently survive CAR T-cell killing in a large cohort of patients. Relapse oftentimes is associated with antigen loss. In this issue, Im and colleagues report a new mechanism of leukemic-cell resistance to anti-CD19 CAR T cells: Leukemic cells can enable a B-cell activation and germinal center reaction signature, which causes CD19 transcriptional downregulation and survival from CAR exposure. See related article by Im et al., p. 1055 (5).
Keyphrases
- cell therapy
- induced apoptosis
- acute myeloid leukemia
- cell cycle arrest
- signaling pathway
- stem cells
- ejection fraction
- newly diagnosed
- mesenchymal stem cells
- gene expression
- endoplasmic reticulum stress
- bone marrow
- transcription factor
- cell proliferation
- free survival
- cell death
- oxidative stress
- replacement therapy
- heat stress